Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C

Castéra, Laurent; Constant, Aymery; Henry, Chantal; Champbenoît, Patrick; Bernard, P; Lédinghen, Victor de; Demotes-Mainard, Jacques; Couzigou, Patrice

doi:10.1111/j.1365-2036.2006.03107.x

Cited by 49 publications

(41 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, nearly 45% of the depression/anxiety disorders appeared in the first month and nearly 65% appeared in the first three months of the Peg-IFN treatment. Likewise in the study of Martin-Santos et al [13], half of the depression and anxiety syndromes appeared in the first month and more than 90% in the first 4 months, and in the study of Castera et al [12], mood disorders associated with Peg-IFN treatment emerged mostly (87%) in the first 12 weeks of 24 weeks of follow-up of patients with hepatitis C [12,13]. This shows that it is important to be alert for depressive symptoms especially in the first 3-4 months of the Peg-IFN treatment.…”

Section: Discussionmentioning

confidence: 74%

“…It is supposed that the central role is played by the interaction between the endocrine system, the immune system, the serotoninergic system, and the opioid receptors [4]. Although untreated depression is a major contributor to dosage reduction or premature discontinuation of the IFN treatment, it is found that depressive symptoms among patients undergoing hepatitis C virus (HCV) treatment are commonly overlooked by routine clinical interviews [9,12]. In addition to depression, anxiety disorders are shown to affect adherence to Peg-IFN treatment in patients with hepatitis C [13].…”

Section: Introductionmentioning

confidence: 99%

“…In addition to depression, anxiety disorders are shown to affect adherence to Peg-IFN treatment in patients with hepatitis C [13]. Some risk factors such as female gender, younger age, past history of a psychiatric disorder, higher baseline depression scores, and lower educational level were defined for the emergence of depression in patients with hepatitis C during IFN treatment [9,12,[14][15][16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Depression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis B

Sertöz

Tunçel

Taşbakan

et al. 2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

Objectives: Interferon (IFN) treatment has many neuropsychiatric side effects such as depression and anxiety disorder. Although untreated depression is a major contributor to dosage reduction or premature discontinuation of the IFN treatment, it is found that depressive symptoms among patients undergoing hepatitis C virus (HCV) treatment are commonly overlooked during routine clinical interviews. Besides depression, anxiety disorders are shown to affect adherence to pegylated IFN (Peg-IFN) treatment in patients with hepatitis C. Despite the occurrence of neuropsychiatric side effects of IFN treatment being widely reported in patients with hepatitis C, there are few studies studying patients infected with hepatitis B virus (HBV). The aim of this prospective study was to evaluate the incidence and risk factors of depressive and anxiety disorders that occur during Peg-IFN treatment of patients with HBV. Methods: The sample consisted of volunteer patients who were diagnosed with HBV infection and who were decided to receive IFN treatment. During the study period, all consecutive patients with HBV infection and who would have IFN treatment were informed about the study and invited to participate. Thirty-seven chronic hepatitis B (CHB) patients were recruited for the study, but four of them were excluded due to psychiatric diagnosis at the initiation of the treatment. Therefore, the sample consisted of 33 patients with CHB, meeting the inclusion criteria. The participants had psychiatric assessment before the treatment and at 1st, 3rd, 6th, and 12th months. At each visit, the subjects were assessed with Clinical Global Impressions Scale, Hamilton Rating Scale for Depression (HRSD), and Hamilton Anxiety Rating Scale (HAM-A). Results: Among the 33 patients with HBV, 22 (66.7%) were men. Mean age was 35.97 ± 10.73 years. While follow-up, 6 patients dropped out from the study. Also, 13 patients were excluded from the study as they developed depression and/or anxiety disorder. Mean baseline HRSD and HAM-A scores were smaller than the following visits' scores. The difference was not statistically significant only for the 12th month assessments. Totally 14 (42.4%) patients developed depression/anxiety disorder during 1 year follow-up. Six (42.86%) of them received the diagnosis at the 1st month, 3 (21.43%) at the 3rd, 4 (28.57%), at 6th months, and 1 (7.14%) at the 12th month. When we compared the patients who developed depression/anxiety disorder with the patients who did not develop any psychiatric disorder, we found that the mean baseline HRSD score (t = 2.303, p = .028) and female percentage (p = .017) were statistically significantly higher in the depression/anxiety disorder group. Conclusions: There is an incidence of 42.4% for depression and/or anxiety disorders during Peg-IFN treatment. Females and patients with subsyndromal depressive symptoms should be referred to a psychiatrist and closely monitored especially for the first three months of the IFN treatment. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Depression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis B

Sertöz

Tunçel

Taşbakan

et al. 2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Depression and mental health issues prevail in the HCV population, represent barriers to treatment with combination therapy, and negatively influence adherence [21,22]. However, numerous studies have shown successful treatment of HCV in patients with depressive symptoms and/or mental health illnesses [23][24][25][26][27].…”

Section: Depression and Adherencementioning

confidence: 99%

Adherence to therapy: Challenges in HCV-infected patients

Pozza¹,

Barakat²,

Barber³

2007

Curr hepatitis rep

View full text Add to dashboard Cite

“…However, 10%–40% additionally develop a full depressive disorder syndrome that can include suicidal ideation, amotivation, social withdrawal, guilt, anhedonia, irritability, anxiety, and crying (2–8). Untreated depression is a major contributor to dosage reductions or treatment discontinuations and consequent risk for viral relapse (9–11). Additionally, many patients with hepatitis C already have preexisting mental health disorders (12) that often go unrecognized (13).…”

Section: Newly Emergent Depression During Ifn-α Therapymentioning

confidence: 99%

Psychiatric Clearance for Patients Started on Interferon-Alpha-Based Therapies

Lotrich¹

2013

AJP

View full text Add to dashboard Cite

Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C

Abstract: SUMMARY BackgroundThe psychiatric side effects of interferon, often responsible for dose reduction or treatment discontinuation, represent a major limitation in the treatment of chronic hepatitis C (CHC).

Cited by 49 publications

References 39 publications

Depression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis B

Depression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis B

Adherence to therapy: Challenges in HCV-infected patients

Psychiatric Clearance for Patients Started on Interferon-Alpha-Based Therapies

Contact Info

Product

Resources

About